Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Allogene Therapeutics Q3 EPS $(0.19) Beats $(0.22) Estimate

Author: Benzinga Newsdesk | November 06, 2025 04:15pm
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 15.18 percent. This is a 40.63 percent increase over losses of $(0.32) per share from the same period last year.

Posted In: ALLO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist